# Expert Panel Critical Review Summary
## AI-Powered Standards Generation Tool - TICKET-014

**Date:** 2026-02-15
**Review Panel:** 5 Diverse Regulatory Experts
**Tool Version:** 5.26.0
**Overall Consensus:** **SIGNIFICANT CONCERNS - Not Ready for Production Use**

---

## Executive Summary

Five independent regulatory experts from different roles evaluated the generate-standards command specification. The consensus is clear: **while the tool has educational value, it poses significant risks for production regulatory use** and overpromises capabilities it cannot deliver.

### Rating Distribution

| Expert Role | Rating | Recommendation |
|-------------|--------|----------------|
| **Standards Testing Engineer** | 3/10 | ❌ Would NOT use or recommend |
| **Regulatory Affairs Manager** | 3/10 | ❌ Would NOT integrate into workflow |
| **Quality Assurance Director** | 3/10 | ❌ REJECT for regulated use |
| **Medical Device Consultant** | 7/10 | ⚠️ Adopt with caveats (time-saver only) |
| **FDA Pre-Submission Specialist** | 4/10 | ❌ DO NOT USE for Pre-Sub planning |

**Average Rating: 4/10**

---

## Critical Cross-Cutting Issues

### 1. **Accuracy Claims Are UNVERIFIED** ⚠️⚠️⚠️

**Finding:** All 5 experts flagged unsubstantiated accuracy claims.

**Testing Engineer:**
> "The spec claims '95% accuracy' but I found a 50% error rate in sample review (6 major errors / 12 total standards in 2 devices). This is NOWHERE NEAR 95%."

**QA Director:**
> "No validation reports exist. validation_reports/ directory is EMPTY. The spec claims multi-agent validation with ≥99.5% coverage threshold, but no auditor or reviewer agent has EVER run."

**RA Manager:**
> "75-85% accuracy for 'medium confidence' standards requires manual verification that takes LONGER than just doing the research correctly. Net productivity: NEGATIVE."

**Consensus:** The accuracy claims lack objective evidence and create **false confidence** that could lead to FDA submission failures.

---

### 2. **Database Coverage Gap: 54 vs. 1,900 Standards** ⚠️⚠️⚠️

**Finding:** Tool covers only 3.5% of FDA-recognized consensus standards.

**Pre-Sub Specialist:**
> "FDA's database has ~1,550-1,671 recognized standards. This tool has 54 (3.5% coverage). A 96.5% gap isn't a 'limitation' – it's regulatory malpractice. Missing critical standards like ASTM F2516 for nitinol stents could cost $200K-400K in delays."

**Testing Engineer:**
> "For a spinal fusion device (OVE), the tool outputs ASTM F1717 but MISSES:
> - ASTM F136 (Ti-6Al-4V material — if titanium alloy used)
> - ISO 10993-11 (systemic toxicity — long-term implant)
> - ASTM F2077 (interbody fusion — if it's a cage)
> - ISO 14607 (non-active surgical implants)
>
> These aren't 'nice to have' — they're SHOWSTOPPERS for FDA clearance."

**Cost of Missing Standards:**
- Re-testing delays: 3-6 months per missed standard
- Additional testing costs: $15K-$150K per standard
- FDA RTA (Refuse to Accept) risk
- Reputation damage with FDA reviewers

---

### 3. **"AI-Powered" Claim is MISLEADING** ⚠️⚠️⚠️

**Finding:** Implementation uses keyword matching, not AI analysis.

**Testing Engineer:**
> "The spec says 'AI-Powered' and 'Autonomous agent analyzes device characteristics.' The actual code is KEYWORD MATCHING:
>
> ```python
> 'cardiovascular': {
>     'keywords': ['heart', 'cardiac', 'catheter'],
>     'standards': [(...)],
> }
> ```
>
> This is either incompetence or fraud. Either way, I wouldn't trust the organization that produced this."

**QA Director:**
> "The spec states: 'AI determines applicable standards based on embedded knowledge base' (line 36). What I found: 262 of 267 generated files (98%) use 'knowledge_based' method, NOT AI. This creates compliance liability."

**Consultant:**
> "If it's keyword matching, call it 'Knowledge-Based Standards Recommendation Engine.' Don't claim 'AI-Powered' when it's a script with if/then rules."

---

### 4. **Compliance and Liability Risks** ⚠️⚠️⚠️

**Finding:** Tool violates 21 CFR 820 design control requirements.

**QA Director (Full Compliance Analysis):**

> **21 CFR 820.30(c) Violation - No Traceability:**
> During FDA audit, I'd be forced to say: "An AI agent determined this standard was applicable based on its embedded knowledge base."
>
> FDA responds: "Show me the documented risk assessment, material characterization data, or guidance citation."
>
> **I have NONE of that.** The AI skips objective evidence entirely.

> **21 CFR 820.70(i) Violation - No Validation:**
> If this tool is used "as part of production or the quality system," I must validate it per FDA requirements:
> - ✗ No validation protocol (IQ/OQ/PQ)
> - ✗ No test cases with known correct answers
> - ✗ No accuracy metrics
> - ✗ No worst-case testing

**Liability Scenario:**
1. Company uses tool → generates standards list
2. Submits 510(k) based on tool output
3. Tool MISSED critical standard (e.g., ISO 10993-4 for thrombogenicity)
4. FDA issues RTA (3-6 month delay, $200K loss)
5. Company sues... **who?**
   - Tool says: "Research use only! You were supposed to verify!"
   - User says: "Tool claimed HIGH confidence and 95% accuracy!"

**QA Director Rating:** 3/10 - **REJECT for regulated use pending major compliance improvements.**

---

### 5. **Time Savings Are OVERSTATED** ⚠️⚠️

**Finding:** Real-world workflows require verification that erases claimed savings.

**RA Manager's Actual Workflow Analysis:**

| Task | Time Without Tool | Time With Tool |
|------|------------------|----------------|
| Identify product code & predicates | 30 min | 30 min (no help) |
| Pull recent 510(k) from FDA | 15 min | 15 min (no help) |
| **Extract standards from predicate** | **10 min** | **SAVED** ✓ |
| **Cross-reference FDA database** | **20 min** | **SAVED** ✓ |
| Check if standards versions current | 15 min | 15 min (tool doesn't do this) |
| Determine if new testing needed | 45 min | 45 min (design-specific) |
| Document rationale for 510(k) | 30 min | 30 min (tool provides reasoning, not formatted prose) |
| Second reviewer sign-off | 15 min | 15 min (required regardless) |
| **TOTAL** | **3 hours** | **2.5 hours** |

**Realistic Savings: 30 min MAX (17% reduction, not 50-67% as claimed)**

**Testing Engineer:**
> "Tool saves 20 minutes on research. But I still need 2-4 hours to verify EVERY determination (because I've seen 50% error rates). Net result: I spend MORE time, not less."

---

### 6. **Missing Critical Context for Real-World Use** ⚠️⚠️

**Finding:** Tool provides standard numbers without actionable information.

**What Tool Provides:**
- `"ISO 10993-1:2018"`
- `"Biological evaluation - Part 1"`
- `"Applicability: ALL devices with patient contact"`

**What Testing Engineers ACTUALLY Need:**

**Testing Engineer's Requirements:**
> "I need to know:
> 1. **Specific test sections within the standard** - ISO 10993-1 has 12 parts. Which ones?
> 2. **Device-specific parameters** - Contact duration (<24hr, 24hr-30d, >30d)? Temperature? Use cycles?
> 3. **Rationale for EXCLUSIONS** - Client asks 'Do we need ISO 10993-10?' I need to justify YES or NO.
> 4. **Test protocol recommendations** - Sample sizes, lead times, accredited lab recommendations.
>
> **This tool provides NONE of the above.**"

**RA Manager:**
> "In Pre-Submission planning, I don't need to know WHICH standards exist. I need to know:
> - Can I use ALTERNATIVE Method X instead of Standard Y?
> - How do I APPLY standard Z to my specific design?
> - Do I need the LATEST version or can I use older recognized version?
> - Can I use NON-consensus methods with good justification?
>
> **The tool answers NONE of these questions.**"

---

## Role-Specific Findings

### Standards Testing Engineer (3/10)

**Core Concerns:**
- **50% error rate** in sample validation (6 errors / 12 standards)
- **Incorrect category assignments** (e.g., IEC 60601-1 for manual non-electrical catheter)
- **Missing critical standards** (e.g., ISO 10993-4 thrombogenicity for blood-contacting devices)
- **No test protocol context** (sample sizes, lead times, cost estimates)

**Liability Assessment:**
> "If I recommend this tool and it misses a critical standard, **I'm liable** for professional negligence. Testing labs get sued when inadequate testing leads to adverse events. AI tools don't carry liability insurance."

**Use Cases Where It Would FAIL:**
1. **Combination devices** - Misses drug/biologic standards (ISO 10993-18 chemical characterization)
2. **Novel materials** - Doesn't know emerging standards (ASTM F3001 for 3D-printed titanium)
3. **Reprocessed devices** - Misses reusable-specific standards (ISO 17664, AAMI ST79)

**Verdict:** "This is a $500 keyword-matching script being marketed as a $50,000 AI validation platform."

---

### Regulatory Affairs Manager (3/10)

**Core Concerns:**
- **RTA Risk** - If tool misses ISO 14971 (Risk Management), 90-day clock resets
- **Verification burden erases savings** - 75-85% accuracy means 3 hours verifying questionable determinations
- **Static knowledge vs. dynamic precedent** - FDA expectations shift quarterly based on recent clearances
- **Competitive intelligence use case is worthless** - "Top 100 product codes" analysis: Never needed this in 10 years

**Trust Threshold Analysis:**
> "Medium confidence = 75-85% accuracy = 1 in 4 determinations might be wrong.
>
> I need ≥98% accuracy to trust regulatory tools. Current confidence thresholds make this tool **NET NEGATIVE for productivity**."

**Real-World Impact:**
- **Time saved:** 30 min (not 2-4 hours)
- **Risk added:** Potential RTA (3-6 month delay, $300K-500K cost)
- **Math:** Risk >> Reward

**Verdict:** "Would NOT integrate into production workflow. Tool creates false confidence that could lead to RTAs."

---

### Quality Assurance Director (3/10)

**Core Concerns:**
- **21 CFR 820.30(c) violation** - No traceability or objective evidence
- **21 CFR 820.70(i) violation** - No validation protocol for automated process
- **Change control nightmare** - Quarterly FDA database updates create perpetual re-validation burden
- **Documentation burden INCREASES** - Need validation protocol, risk assessment, verification records

**Audit Scenario:**
> **FDA Investigator:** "Show me the rationale for ISO 10993-11 selection."
>
> **Me:** "An AI said devices with systemic exposure require it."
>
> **FDA:** "That's a conclusion, not objective evidence. Where's the TRACEABLE RATIONALE linking your specific device design to this standard?"
>
> **Me:** "...I don't have it."
>
> **Result:** 483 observation for inadequate design controls.

**Liability Trap:**
- Tool says: "Research use only!"
- FDA says: "You're responsible for complete submissions."
- My CEO says: "Why did you approve this tool?"

**Verdict:** "REJECT for regulated use. Creates compliance risks and lacks audit-ready documentation."

---

### Medical Device Consultant (7/10) - ONLY POSITIVE REVIEW

**Core Finding:** Tool is a time-saver, NOT a replacement.

**Why It's NOT a Threat:**
> "Standards identification is the appetizer, not the main course. Clients hire me for:
> - Writing test protocols ($3K-5K per device)
> - Interpreting test results
> - Explaining to FDA reviewers why we chose X over Y
> - Navigating deficiencies when tests fail
>
> This tool gives them a shopping list, but they still need me to cook the meal."

**Business Impact Analysis:**
- **What I lose:** $600-$1,200 per device (basic standards lookup)
- **What I keep:** $10K-20K per device (interpretation, strategy, FDA negotiation)
- **Net impact:** Shifts my work from commodity to premium consulting

**Use Cases Where It HELPS:**
1. **Discovery call prep** - Quick baseline for scoping calls
2. **Pre-Sub package upsell** - Tool gives baseline, I focus on gap analysis ($3K vs. $2.4K)
3. **Portfolio assessment** - Enables $15K projects by saving 10 hours

**Pricing Recommendation:**
- **Would pay:** $500-$1,000/year
- **Current value:** $500-$750/year
- **To reach $2,500/year:** Need competitive intel + cost estimates + test lab pricing

**Verdict:** "ACCELERATOR, not threat. Positions me as tech-forward consultant. Creates MORE touchpoints (education calls after AI output)."

---

### FDA Pre-Submission Specialist (4/10)

**Core Concerns:**
- **96% standards gap** (54 vs. 1,900 FDA-recognized standards)
- **Cannot capture reviewer variability** (different reviewers expect different standards)
- **Quarterly updates too slow** (2023 Cybersecurity Guidance changed expectations overnight)
- **Misaligned with actual Pre-Sub discussions** (FDA discusses HOW to apply standards, not WHICH standards exist)

**FDA Reality Check:**
> "In 200+ Pre-Sub meetings, I've seen ZERO cases where FDA said: 'Your standards list is incomplete.'
>
> I've seen DOZENS where FDA said: 'Your test protocol for Standard X doesn't match our expectations' or 'You cite ISO 10993-1, but your biological evaluation plan doesn't address all endpoints.'
>
> **The problem is never WHICH standards. The problem is always HOW to apply them.**"

**Costly Example:**
> **Device:** Nitinol stent (Product Code NMX)
>
> **Tool Output:** ISO 25539-1, ISO 10993 series (comprehensive!)
>
> **CRITICAL MISSING:** ASTM F2516 (Tension Testing of Nitinol) - NOT in 54-standard database
>
> **What Happens:** Company proceeds to Pre-Sub. FDA asks: "Where's your F2516 data?" Company delays submission 4-6 months for testing.
>
> **Cost:** $200K-400K.

**When It MIGHT Help (4 points):**
1. Earliest concept stage (pre-prototype budgeting)
2. Competitor intelligence (with caveats about missing 96% of standards)
3. Training junior RA staff (educational value only)
4. Portfolio gap analysis (internal planning)

**When It Would MISLEAD (6 points):**
1. Pre-Submission planning (as spec claims)
2. Novel device development (missing specialty standards)
3. Division-specific expectations (cannot capture reviewer variability)
4. Guidance-driven requirements (3-12 months behind regulatory shifts)
5. Predicate-based strategy (doesn't know what predicates tested to)
6. International submissions (FDA ≠ EU MDR ≠ Japan PMDA)

**Verdict:** "DO NOT USE for Pre-Sub planning. Limited educational value. Dangerous for actual regulatory decisions."

---

## Cross-Panel Recommendations

### Unanimous Rejection Reasons (All 5 Experts)

1. **Accuracy claims lack validation**
   - No independent testing
   - No validation protocol
   - Sample review shows 50% error rate vs. claimed 95%

2. **Database coverage insufficient**
   - 54 standards vs. 1,900+ FDA-recognized
   - Missing critical device-specific standards
   - Missing emerging guidance-driven standards

3. **Marketing claims mislead users**
   - "AI-Powered" but implementation is keyword matching
   - "95% accuracy" but no validation reports exist
   - "Ensure complete testing coverage" but 96% gap creates massive holes

4. **Time savings overstated**
   - Claimed: 2-4 hours saved
   - Actual: 30 min saved (after mandatory verification)
   - Net productivity: NEGATIVE (for RA Manager, Testing Engineer, QA Director)

5. **Liability and compliance risks**
   - No objective evidence for design controls (21 CFR 820.30)
   - No validation for automated processes (21 CFR 820.70(i))
   - Disclaimers shift ALL risk to user without verification framework

### What Would Change Their Minds (Required Improvements)

**All 5 experts converged on similar requirements:**

#### 1. **Validate Accuracy Claims** (Testing Engineer, QA Director, RA Manager)
- Hire regulatory consultant to manually review 500 product codes
- Compare tool output to consultant determinations
- Publish validation report with real accuracy metrics
- Get ISO 17025-accredited lab to verify outputs

#### 2. **Connect to Full FDA Database** (Pre-Sub Specialist, RA Manager)
- Use FDA's 1,900+ standard database API
- Update DAILY (not quarterly)
- Pull recognized versions and withdrawal dates automatically
- Show which standards FDA has withdrawn or superseded

#### 3. **Add Predicate Analysis** (RA Manager, Pre-Sub Specialist, Consultant)
- Scrape 510(k) summaries for predicates in same product code
- Extract which standards predicates cite in Section 17
- Show: "83% of successful DQY clearances cite ISO 11070 + ASTM F2394"
- Shift from "theoretical standards" to "proven clearance path"

#### 4. **Provide Verification Framework** (QA Director, RA Manager)
- Tool generates DRAFT standards list
- User MUST verify each standard against FDA database + predicates + risk assessment
- User documents verification (creates objective evidence for DHF)
- Tool tracks verification status (prevents use of unverified output)

#### 5. **Add Test Protocol Context** (Testing Engineer, RA Manager)
- Specific test sections (ISO 10993-1 endpoints: 5.1, 5.2, 5.4)
- Sample size requirements
- Typical lead times
- Estimated costs per standard ($5-10K, $10-25K, $25-50K ranges)
- Accredited testing labs that offer these tests

#### 6. **Remove Misleading Claims** (All 5 Experts)
- Don't call it "AI-Powered" if it's keyword matching
- Don't claim "95% accuracy" without validation data
- Add prominent warning: "REQUIRES INDEPENDENT VERIFICATION"
- Clarify limitations upfront, not buried in disclaimers

---

## Detailed Score Breakdown

| Criterion | Test Eng | RA Mgr | QA Dir | Consultant | Pre-Sub | Average |
|-----------|----------|--------|--------|------------|---------|---------|
| **Accuracy** | 1/10 | 2/10 | 2/10 | 5/10 | 3/10 | 2.6/10 |
| **Completeness** | 2/10 | 3/10 | 2/10 | 6/10 | 2/10 | 3.0/10 |
| **Reliability** | 2/10 | 2/10 | 1/10 | 7/10 | 3/10 | 3.0/10 |
| **Time Savings** | 2/10 | 2/10 | 4/10 | 8/10 | 4/10 | 4.0/10 |
| **Compliance** | 0/10 | 3/10 | 1/10 | N/A | 3/10 | 1.8/10 |
| **Liability Protection** | 0/10 | 1/10 | 1/10 | N/A | 3/10 | 1.3/10 |
| **Regulatory Value** | 3/10 | 3/10 | 3/10 | 7/10 | 4/10 | 4.0/10 |

**Overall Average: 4.0/10**

---

## Use Case Viability Assessment

| Use Case (per Spec) | Viable? | Expert Consensus |
|---------------------|---------|------------------|
| **New Device Development** | ⚠️ PARTIAL | Consultant: Yes (preliminary research)<br>RA Manager: No (still need full verification)<br>Testing Engineer: No (missing test protocols) |
| **Competitive Intelligence** | ❌ NO | RA Manager: "Never needed this in 10 years"<br>Pre-Sub: "Product codes too broad to be useful"<br>Consultant: "Need device-specific data, not aggregates" |
| **Portfolio Assessment** | ⚠️ LIMITED | Consultant: Yes (shared resource planning)<br>QA Director: No (creates compliance burden)<br>Testing Engineer: No (only 54 standards covered) |
| **Pre-Submission Planning** | ❌ NO | Pre-Sub: "DO NOT USE - 96% gap is dangerous"<br>RA Manager: "Creates more work than it saves"<br>QA Director: "Lacks objective evidence for DHF" |

**APPROVED Use Cases (All 5 Experts Agree):**
1. ✅ **Training junior RA staff** (educational value, with heavy disclaimers)
2. ✅ **Preliminary R&D concept budgeting** ("Will this need 5 standards or 25?")
3. ✅ **Consultant discovery call prep** (quick baseline for scoping)

**PROHIBITED Use Cases (All 5 Experts Agree):**
1. ❌ **Design input documentation in DHF** (QA Director: violates 21 CFR 820.30)
2. ❌ **Standards justification for 510(k) submissions** (RA Manager: RTA risk)
3. ❌ **Replacing RA professional standards analysis** (Testing Engineer: 50% error rate)
4. ❌ **Sole basis for test protocol selection** (All experts: missing critical context)

---

## Critical Failure Scenarios

### Scenario 1: Spinal Fusion Device (OVE)

**Tool Output:**
- ASTM F1717 (Spinal Implant Constructions) - HIGH confidence
- ISO 13485, ISO 14971 - HIGH confidence
- ISO 10993-1, -5, -10 - HIGH confidence

**What's MISSING (per Testing Engineer):**
- ASTM F2077 (Interbody Fusion Devices) - **IF it's a cage**
- ASTM F136 (Ti-6Al-4V material) - **IF titanium alloy used**
- ISO 10993-11 (Systemic Toxicity) - **Long-term implant requires this**
- ISO 14607 (Non-active surgical implants) - **General implant standard**

**Cost of Failure:**
- Missing ASTM F2077: $35K re-testing + 8-week delay
- Missing ISO 10993-11: $25K re-testing + 12-week delay (long-term study)
- **Total:** $60K + 20 weeks (5 months)

**FDA Impact:**
- RTA if submitted without these standards
- Or major deficiency letter in review
- Clearance timeline extends by 6-9 months

### Scenario 2: Intravascular Lithotripsy Catheter (DQY)

**Tool Output (per Pre-Sub Specialist):**
- Generic DQY standards: ISO 10993 series, ISO 11070, IEC 60601-1

**What FDA ACTUALLY Expects:**
- IEC 61846 (lithotripters) adapted for catheters
- IEC 62127 series (acoustic output measurements)
- Bioeffects data (no consensus standard - company-validated protocol)
- Electrical safety for HIGH VOLTAGE pulse generator
- Novel mechanism requires extensive Pre-Sub discussion

**Cost of Failure:**
- Major deficiency letter
- 4-month delay
- $400K (additional testing + consultant fees)

**Why Tool Failed:**
- Novel mechanism not captured by "catheter" keywords
- Acoustic output standards not in 54-standard database
- High-voltage pulse generator safety beyond basic IEC 60601-1

### Scenario 3: AI-Powered Diabetic Retinopathy Screening (QKQ)

**Tool Output (per Pre-Sub Specialist):**
- ISO 13485, ISO 14971, IEC 62304, IEC 82304-1, IEC 62366-1

**What FDA ACTUALLY Discusses in Pre-Sub:**
- Clinical validation per 2022 guidance (not a consensus standard)
- Algorithm transparency per 2021 AI/ML guidance (no standard)
- Real-world performance monitoring plan (no standard)
- Demographic subgroup bias analysis (FDA-specific expectation)

**Why Tool Is IRRELEVANT:**
- Consensus standards are "table stakes" - FDA assumes you did them
- 100% of Pre-Sub discussion focuses on clinical validation design, not standards
- The regulatory strategy is everything; standards list is trivial for SaMD

---

## Expert Panel Unanimous Conclusion

**NOT READY FOR PRODUCTION REGULATORY USE**

### Approved for:
- ✅ Educational/training purposes (junior RA staff learning standards categories)
- ✅ Preliminary R&D budgeting (ballpark testing cost estimates)
- ✅ Consultant time-savers (discovery call prep, portfolio scoping)

### Prohibited for:
- ❌ Design History File documentation (lacks objective evidence)
- ❌ FDA submission standards justification (accuracy unvalidated, coverage gaps)
- ❌ Pre-Submission planning (cannot capture reviewer expectations)
- ❌ Test lab work orders (missing critical device-specific standards)

### Required Actions Before Production Use:

**CRITICAL (Must Fix):**
1. Validate accuracy claims with independent testing (500+ product codes)
2. Connect to full FDA database (1,900+ standards, not 54)
3. Add predicate analysis (what actually clears in this product code)
4. Implement verification framework (requires user sign-off with objective evidence)
5. Remove misleading "AI-Powered" and "95% accuracy" claims
6. Add prominent disclaimers in UI (not just buried in spec)

**HIGH PRIORITY (Should Fix):**
7. Add test protocol context (sample sizes, costs, lead times)
8. Integrate FDA guidance documents (division-specific expectations)
9. Add version guidance (which edition of standard to use)
10. Implement change control for quarterly database updates

**NICE TO HAVE (Would Enhance):**
11. Cost estimation per standard
12. Test lab directory integration
13. Pre-Sub question templates
14. Competitive intelligence features (if product code analysis redesigned)

---

## Final Recommendation to Development Team

**From 5 Regulatory Experts:**

> "This tool has value as a **research assistant** and **educational resource**, but it is **NOT production-ready** for FDA regulatory submissions.
>
> The gap between **what the spec claims** (AI-powered, 95% accurate, ensures complete testing coverage) and **what the tool delivers** (54-standard keyword matcher with unvalidated accuracy) creates **significant liability risk** for any company that relies on it for 510(k) submissions.
>
> **Our recommendation:**
> 1. **Reposition as educational/research tool** (not production regulatory tool)
> 2. **Validate accuracy claims** (or remove them)
> 3. **Connect to full FDA database** (1,900+ standards)
> 4. **Add verification requirements** (force users to independently verify ALL determinations)
> 5. **Test with 500+ real product codes** (publish validation report)
>
> **Only then** would we recommend this tool to regulatory professionals for production use."

---

**Expert Panel Signatures:**
- Standards Testing Engineer (15 years, contract testing lab)
- Regulatory Affairs Manager (10 years, 50+ 510(k) submissions)
- Quality Assurance Director (ISO 13485 + 21 CFR Part 820 expert)
- Independent Medical Device Consultant ($300/hour billing rate)
- FDA Pre-Submission Specialist (Former CDRH reviewer, 200+ Pre-Subs)

**Date:** 2026-02-15
**Review Duration:** ~6 hours (20+ hours total expert time)
